secwatch.observer — SEC 8-K summary
======================================

Issuer:     VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK:        0000875320
Form:       8-K
Filed at:   2025-08-04T23:59:59+00:00
Accession:  0000875320-25-000213
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Vertex Q2 revenue $2.96B (+12% YoY); CSO Altshuler to retire Aug 2026; Bunnage to succeed
--------------------------------------------------------------------------------

- Q2 revenue $2.96B (+12% YoY); GAAP net income $1.0B vs loss $3.6B last yr; non-GAAP net income $1.2B vs loss $3.3B
- Reiterated FY25 revenue guidance $11.85-$12.0B; combined R&D/SG&A guidance unchanged
- CSO David Altshuler to retire Aug 1, 2026; Mark Bunnage becomes CSO effective Feb 1, 2026 as planned transition
- VX-993 Phase 2 acute pain study missed primary endpoint; Vertex not advancing it as monotherapy
- CASGEVY: ~115 patients had first cell collection, 29 infused; JOURNAVX: >110,000 prescriptions filled

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/0000875320-25-000213-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/875320/000087532025000213/vrtx-20250804.htm
  HTML page:      https://secwatch.observer/filing/0000875320-25-000213

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer